Combining radiographic findings from [68Ga]PSMA PET/CT with immunohistochemical studies targeting biomarkers such as PSA and PSAP, as shown in this case, enables more accurate identification of metastatic prostate carcinomas, compared to other non-prostatic etiologies. Here, FOLH1 is linked to prostate carcinoma.